Health ❯ Healthcare ❯ Pharmaceuticals

Clinical Trials

Drug Development Weight Loss Drugs Cancer Treatments Alzheimer's Disease Gene Therapy Cancer Treatment Drug Efficacy Major Depressive Disorder Drug Safety Weight Loss Treatments Hypertension Obesity Treatment Phase 3 Trials Atopic Dermatitis Phase 3 Studies Efficacy Studies Duchenne Muscular Dystrophy Study Results Cardiovascular Health Experimental Drugs Regulatory Affairs Breast Cancer Multiple Myeloma Stroke Prevention Eli Lilly Monoclonal Antibodies Semaglutide Phase 2 Trials Pain Management Pulmonary Sarcoidosis Tirzepatide Obesity Treatments Mental Health Eli Lilly & Company Antiviral Drugs Orforglipron Asthma Alopecia Cardiovascular Risk Reduction Treatment Guidelines Nebulized Tyvaso Biopharmaceuticals C3 Glomerulopathy (C3G) Product Development Benefit-Risk Assessment Weight Loss Medications Cardiovascular Risk Epilepsy Treatments Lecanemab Olezarsen EMBER-3 Study VTX3232 EMBER-3 Neurological Disorders Lung Cancer Treatments Weight Loss Eczema Epilepsy Narcolepsy Treatment Phase III Trials Drug Approval Lung Cancer Cochrane Reviews Alcohol Use Disorder COPD Late-stage Studies Garetosmab Autoimmune Diseases Cannabis Medications Ulcerative Colitis FDA Advisory Committee DYNE-251 Chronic Myeloid Leukemia Giredestrant Obefazimod IgA Nephropathy Type 2 Diabetes Vaccine Efficacy Risk-Based Oversight Systems NG101 Patient Safety Investigational Drugs GLP-1 Receptor Agonists Chronic Lymphocytic Leukemia FDA Approval Geographic Atrophy Multiple Sclerosis Side Effects Dementia Treatments Phase Ib Studies Anticoagulants Weight Management Ziihera Alzheimer's Treatment Novo Nordisk Diabetes Medications HIV Treatment COVID-19 Treatments Selective Estrogen Receptor Modulators Nuzolvence and Blujepa

Lilly Reports Zepbound Plus Taltz Beat Taltz Alone in Psoriatic Arthritis Trial

The company released topline, open-label results that await full review.

FDA Approves Vanda’s Nereus, First New Motion Sickness Treatment in Over 40 Years

AstraZeneca’s LATIFY Phase 3 Finds No Survival Benefit for Ceralasertib Plus Imfinzi in Pre-Treated NSCLC

Athira Pharma Secures Exclusive Lasofoxifene Rights, Raises $90 Million to Advance Phase 3 Breast Cancer Program

FDA Clears First New Oral Gonorrhea Antibiotics in Over 30 Years

Gilead’s BIC/LEN HIV Tablet Matches Biktarvy in Phase 3 Switch Trial

Lilly’s Triple‑Agonist Retatrutide Delivers Up to 28.7% Weight Loss in Phase 3, Easing Knee Pain

Tucatinib Added to First-Line HER2 Maintenance Prolongs Progression-Free Survival in Phase 3 Trial

Terns’ TERN-701 Shows Strong CML Responses in CARDINAL, Setting 320 mg and 500 mg Phase 2 Doses

Wave Life Sciences Soars on Obesity Trial Signal as It Begins $250 Million Stock Offering

Pirtobrutinib Extends First-Line PFS vs BR and Shows Higher Response Rates Than Ibrutinib in CLL/SLL

aTyr Pharma Lead‑Plaintiff Deadline Hits as Rival Firms Vie to Steer Securities Case

Pliant’s PLN-101095 With Keytruda Shows Early Responses in PD-1–Refractory Solid Tumors

Novo Nordisk’s Oral Semaglutide Fails to Slow Alzheimer’s in Dual Phase 3 Trials

Junshi’s Subcutaneous Toripalimab Matches IV in Phase 3 NSCLC Trial as Company Prepares NDA

Bayer Stroke Drug Asundexian Hits Phase III Goals, Shares Jump

Yale Study Finds Only 24% of Medicines Tested Reach Trial-Host Countries Within Five Years

Zymeworks Shifts to Royalty Model After Ziihera’s Phase 3 Win in HER2‑Positive Gastroesophageal Cancer

FDA Adds Boxed Liver Warning and Limits Elevidys to Ambulatory Boys 4 and Up

Jasper Therapeutics Investors Face Lead Plaintiff Deadline in Securities Class Action